Hypothesis

Senescent fibroblasts that upregulate FasL not only evade immune clearance but also actively re‑program recruited macrophages toward a profibrotic phenotype via reverse signaling that stimulates STAT3‑dependent TGF‑β1 secretion. Blocking FasL will shift macrophages to a pro‑repair state, reducing collagen deposition while preserving the early, beneficial senescent cell functions needed for wound closure.

Mechanistic Rationale

In acute injury, transient senescent fibroblasts secrete PDGF‑AA to stimulate myofibroblast differentiation and accelerate repair[1]. When these cells persist, they increase surface FasL, which kills cytotoxic lymphocytes attempting clearance[4]. FasL engagement is known to deliver reverse signals into the expressing cell, but recent data show that FasL on stromal cells can also trigger signaling cascades in Fas‑positive immune cells[6]. We propose that FasL–Fas interaction on macrophages activates Src family kinases, leading to STAT3 phosphorylation and transcriptional up‑regulation of TGF‑β1. This cytokine then drives neighboring fibroblasts to adopt a myofibroblast fate, amplifying extracellular matrix deposition and creating a feed‑forward loop of fibrosis.

Experimental Approach

1. Model – Use dorsal excisional wounds in 8‑week‑old C57BL/6 mice. Generate senescent fibroblasts locally by irradiating a 2 mm × 2 mm square of dermis (2 Gy) 24 h before wounding, a method that yields p16^INK4a^‑positive cells without causing necrosis.
2. Intervention – Treat wounds with either (a) an anti‑FasL blocking antibody (clone MFL3, 10 µg dose intraperitoneally every 48 h) or (b) isotype control. Include a group where senescent fibroblasts are genetically ablated using p16‑3MR mice administered ganciclovir to confirm specificity.
3. Readouts –
   • Day 3: flow cytometry of wound digests to quantify macrophage subsets (F4/80^+CD206^+ vs. F4/80^+CD86^+) and intracellular phospho‑STAT3.
   • Day 7: ELISA of wound homogenates for TGF‑β1 and PDGF‑AA.
   • Day 14: histological assessment of collagen deposition (picrosirius red stain, quantified by polarized light) and re‑epithelialization length.
   • Throughout: imaging of senescent cell burden (p16^INK4a^‑GFP reporter) to ensure that FasL blockade does not accelerate clearance beyond physiological rates.
4. Controls – Wounds without induced senescence, wounds with senescence but receiving FasL‑IgG, and wounds treated with a senolytic (dasatinib + quercetin) to contrast outcomes.

Expected Outcomes

If the hypothesis is correct, anti‑FasL treatment will:

• Reduce the proportion of CD206^+ macrophages and lower phospho‑STAT3 levels in macrophages by ~40 % compared with control (p < 0.01).
• Decrease TGF‑β1 concentration in wound fluid by ~35 % while maintaining PDGF‑AA levels comparable to untreated senescent wounds.
• Result in a ~30 % reduction in collagen area at day 14 without significantly altering re‑epithelialization speed (difference < 5 % vs. control), indicating that the early pro‑repair SASP is preserved.
• Show no increase in senescent cell clearance beyond the baseline rate, confirming that the effect is due to altered macrophage polarization rather than accelerated removal.

Conversely, FasL blockade should not worsen wound closure, and senolytic treatment will reduce both PDGF‑AA and TGF‑β1, leading to delayed early closure but lower fibrosis—a pattern that distinguishes the two strategies.

Falsifiability

Failure to observe a statistically significant reduction in macrophage phospho‑STAT3 or TGF‑β1 upon FasL inhibition, or a concomitant decline in PDGF‑AA‑mediated repair metrics, would refute the proposed reverse‑signaling mechanism. Similarly, if collagen deposition remains unchanged despite macrophage phenotype shifts, the link between FasL‑driven macrophage reprogramming and fibrosis would be unsupported.